Alnylam Pharmaceuticals (NASDAQ:ALNY) had its target price trimmed by BMO Capital Markets from $165.00 to $160.00 in a research report sent to investors on Friday morning. The firm currently has an outperform rating on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on ALNY. Morgan Stanley dropped their price objective on shares of Alnylam Pharmaceuticals from $128.00 to $118.00 and set an equal weight rating for the company in a research note on Friday. Leerink Swann increased their price objective on shares of Alnylam Pharmaceuticals from $132.00 to $135.00 and gave the company a market perform rating in a research note on Thursday, January 25th. B. Riley began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, November 1st. They issued a buy rating and a $240.00 price objective for the company. Piper Jaffray Companies restated a buy rating and issued a $182.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Sunday, January 7th. Finally, Needham & Company LLC restated a buy rating and issued a $152.00 price objective (up previously from $125.00) on shares of Alnylam Pharmaceuticals in a research note on Friday, November 3rd. Three investment analysts have rated the stock with a sell rating, seven have issued a hold rating, fifteen have issued a buy rating and one has assigned a strong buy rating to the stock. The company currently has an average rating of Buy and a consensus price target of $126.98.

Alnylam Pharmaceuticals (ALNY) traded down $0.40 during trading hours on Friday, reaching $115.92. 1,304,954 shares of the company traded hands, compared to its average volume of 887,777. The firm has a market cap of $11,360.00, a PE ratio of -21.43 and a beta of 2.68. Alnylam Pharmaceuticals has a 1 year low of $40.93 and a 1 year high of $147.63. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.38) by ($0.10). Alnylam Pharmaceuticals had a negative net margin of 545.95% and a negative return on equity of 48.88%. The company had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same quarter in the previous year, the company earned ($1.32) earnings per share. Alnylam Pharmaceuticals’s revenue for the quarter was up 116.6% compared to the same quarter last year. research analysts forecast that Alnylam Pharmaceuticals will post -5.69 EPS for the current fiscal year.

In other news, SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total value of $757,378.80. Following the sale, the senior vice president now owns 17,749 shares of the company’s stock, valued at approximately $2,151,178.80. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Michael Mason sold 36,745 shares of the company’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $131.59, for a total transaction of $4,835,274.55. Following the completion of the sale, the vice president now directly owns 6,352 shares in the company, valued at approximately $835,859.68. The disclosure for this sale can be found here. In the last ninety days, insiders sold 220,409 shares of company stock worth $28,667,017. 4.30% of the stock is owned by insiders.

Institutional investors and hedge funds have recently bought and sold shares of the company. Verition Fund Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth about $1,060,000. Gotham Asset Management LLC bought a new stake in Alnylam Pharmaceuticals during the 2nd quarter worth about $772,000. Bradley Foster & Sargent Inc. CT grew its holdings in Alnylam Pharmaceuticals by 100.1% during the 3rd quarter. Bradley Foster & Sargent Inc. CT now owns 8,235 shares of the biopharmaceutical company’s stock worth $968,000 after acquiring an additional 4,120 shares during the last quarter. WINTON GROUP Ltd bought a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth about $10,633,000. Finally, First Trust Advisors LP grew its holdings in Alnylam Pharmaceuticals by 25.3% during the 3rd quarter. First Trust Advisors LP now owns 784,619 shares of the biopharmaceutical company’s stock worth $92,185,000 after acquiring an additional 158,288 shares during the last quarter. 88.39% of the stock is currently owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals (ALNY) Given New $160.00 Price Target at BMO Capital Markets” was published by Daily Political and is the property of of Daily Political. If you are reading this news story on another publication, it was illegally copied and republished in violation of United States & international copyright law. The legal version of this news story can be viewed at https://www.dailypolitical.com/2018/02/10/alnylam-pharmaceuticals-alny-given-new-160-00-price-target-at-bmo-capital-markets.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.